ProKidney Corp. (PROK)
NASDAQ: PROK · Real-Time Price · USD
1.690
-0.050 (-2.87%)
At close: Nov 22, 2024, 4:00 PM
1.710
+0.020 (1.18%)
After-hours: Nov 22, 2024, 7:24 PM EST

Company Description

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States.

The company’s lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.

ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.

ProKidney Corp.
ProKidney logo
Country United States
Founded 2015
Industry Biotechnology
Sector Healthcare
Employees 163
CEO Bruce Culleton

Contact Details

Address:
2000 Frontis Plaza Blvd., Suite 250
Winston-Salem, North Carolina 27103
United States
Phone 336 999 7028
Website prokidney.com

Stock Details

Ticker Symbol PROK
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001850270
ISIN Number KYG7S53R1049
Employer ID 98-1586514
SIC Code 2836

Key Executives

Name Position
Dr. Bruce Culleton M.D. Chief Executive Officer and Director
Dr. Timothy A. Bertram D.V.M., Ph.D. Founder
James Coulston CPA Chief Financial Officer
Todd C. Girolamo Esq., J.D., M.B.A. Chief Legal Officer and Secretary
Carla Poulson Chief People Officer
Dr. Joseph M. Stavas M.D., M.P.H. Senior Vice President of Interventional Procedures and Patient Safety
Dr. Darin J. Weber Ph.D. Chief Reg. Off, SVice President and Head of Global Reg. Affairs, Quality Mgmt, Biometrics and Market Access
Nikhil L. Pereira-Kamath Chief Business Officer
Richard Williams Senior Vice President of Information Technology
Dr. Emily Butler Ph.D. Senior Vice President of Biometric

Latest SEC Filings

Date Type Title
Nov 22, 2024 8-K Current Report
Nov 12, 2024 10-Q Quarterly Report
Nov 12, 2024 8-K Current Report
Nov 8, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Nov 8, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Oct 22, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Oct 18, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Sep 19, 2024 144 Filing
Sep 3, 2024 8-K Current Report
Aug 9, 2024 10-Q Quarterly Report